Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Fennec Pharmaceuticals (FENC) over the last 6 years, with Q3 2025 value amounting to 1.52%.

  • Fennec Pharmaceuticals' EBITDA Margin rose 730700.0% to 1.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.02%, marking a year-over-year decrease of 154300.0%. This contributed to the annual value of 5.4% for FY2024, which is 655000.0% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its EBITDA Margin stood at 1.52% for Q3 2025, which was up 730700.0% from 28.31% recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' EBITDA Margin registered a high of 43555.56% during Q2 2021, and its lowest value of 314.25% during Q1 2023.
  • Its 5-year average for EBITDA Margin is 4300.0%, with a median of 9.23% in 2025.
  • In the last 5 years, Fennec Pharmaceuticals' EBITDA Margin crashed by -347678400bps in 2022 and then skyrocketed by 3684100bps in 2024.
  • Over the past 5 years, Fennec Pharmaceuticals' EBITDA Margin (Quarter) stood at 7587.27% in 2021, then tumbled by -86bps to 1047.37% in 2022, then plummeted by -102bps to 18.67% in 2023, then surged by 37bps to 11.79% in 2024, then surged by 87bps to 1.52% in 2025.
  • Its EBITDA Margin was 1.52% in Q3 2025, compared to 28.31% in Q2 2025 and 9.23% in Q1 2025.